Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Efficacy and Safety of ETC-1002 in Participants With Statin Intolerance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* A history of statin intolerance that began during statin treatment and resolved within 4 weeks of stopping the statin treatment~* For participants on current lipid-regulating drugs - LDL-C 100-220 milligrams per deciliter (mg/dL) and triglycerides \<350 mg/dL (prior to wash-out of all lipid-regulating drugs and supplements)~* For participants not on current lipid-regulating drugs - LDL-C 115-270 mg/dL and fasting TG \<400 mg/dL~Key Exclusion Criteria:~* Acute significant cardiovascular disease~* Poorly controlled hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- ETC-1002 (Type: EXPERIMENTAL): ETC-1002 treatment, once daily oral
- Placebo (Type: PLACEBO_COMPARATOR): Placebo treatment, once daily oral

Based on this trial design, predict the completion outcome and termination type (if applicable).